TOKYO—Japan's Yokogawa Electric Corp. has purchased polymer manufacturing solutions provider Fluence Analytics, the companies announced in February.
Terms of the acquisition between Fluence Analytics and the Tokyo-based electrical engineering and software company were not released.
Established in 2013, Houston-based Fluence Analytics provides patented, real-time process analytics and control solutions to polymer and biopharmaceutical companies worldwide. One of its main offerings is an Automatic Continuous Online Monitoring of Polymerization Reactions (ACOMP), which continuously monitors and measures these polymerization reactions.
Fluence Analytics now operates as Yokogawa Fluence Analytics, but will maintain that Fluence brand, according to CEO Jay Manouchehri.
"As of now, we operate as a standalone and will be fairly autonomous," he said.
Fluence Analytics entered a business collaboration with Yokogawa in 2021 that helped the then eight-year-old company improve its access to technology and data analytics, and take advantage of Yokogawa's sales and distribution reach.
At the time, Yokogawa Electric and Fluence Analytics said that under the collaboration agreement they jointly would expand and accelerate the deployment of ACOMP systems. For more than a year, Yokogawa served as Fluence Analytics' exclusive distributor of ACOMP systems in Asia, the Middle East and North Africa, and supported engineering, sales and system integration with customers.
Since beginning their collaboration in August 2021, Fluence Analytics and Yokogawa have been exploring the expansion of existing business opportunities. Following the acquisition, Fluence Analytics will integrate its operations with Yokogawa's existing business and further enhance its technological capabilities.
In addition to ACOMP, the Fluence Analytics product portfolio includes an innovative lab instrument designed to dramatically accelerate and optimize the development of novel biotherapeutics, the firms said in a news release. The instrument enables the rapid assessment and real-time monitoring of the stability of therapeutic proteins, peptides, and other biopolymers under various thermal, mechanical, and chemical stress conditions.
Fluence participated in a $7.5 million financing with other investors in 2021, including Energy Innovation Capital, Diamond Edge Ventures—a division of Mitsubishi Chemical Holdings Corp.—and JSR Corp. Additional capital financing was provided through strategic and individuals investors as early as 2017.